Literature DB >> 27856165

The impact of impaired macrophage functions in cystic fibrosis disease progression.

Manuella Lévêque1, Sophie Le Trionnaire2, Paola Del Porto3, Corinne Martin-Chouly4.   

Abstract

The underlying cause of morbidity in cystic fibrosis (CF) is the decline in lung function, which results in part from chronic inflammation. Inflammation and infection occur early in infancy in CF and the role of innate immune defense in CF has been highlighted in the last years. Once thought simply to be consumers of bacteria, macrophages have emerged as highly sensitive immune cells that are located at the balance point between inflammation and resolution of this inflammation in CF pathophysiology. In order to assess the potential role of macrophage in CF, we review the evidence that: (1) CF macrophage has a dysregulated inflammatory phenotype; (2) CF macrophage presents altered phagocytosis capacity and bacterial killing; and (3) lipid disorders in CF macrophage affect its function. These alterations of macrophage weaken innate defense of CF patients and may be involved in CF disease progression and lung damage.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Inflammation; Lipid homeostasis; Macrophage; Phagocytosis

Mesh:

Year:  2016        PMID: 27856165     DOI: 10.1016/j.jcf.2016.10.011

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  28 in total

1.  Cystic Fibrosis Plasma Blunts the Immune Response to Bacterial Infection.

Authors:  Xi Zhang; Amy Pan; Shuang Jia; Justin E Ideozu; Katherine Woods; Kathleen Murkowski; Martin J Hessner; Pippa M Simpson; Hara Levy
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

2.  The Phagocytosis of Blood Leukocytes from Cystic Fibrosis Patients is not Impaired in General.

Authors:  Laura Leuer; Angelika Krill; Heinrike Wilkens; Gudrun Wagenpfeil; Markus Bischoff; Carola Meier; Robert Bals; Thomas Tschernig
Journal:  Lung       Date:  2019-11-09       Impact factor: 2.584

3.  Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.

Authors:  Roxanna Barnaby; Katja Koeppen; Amanda Nymon; Thomas H Hampton; Brent Berwin; Alix Ashare; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-16       Impact factor: 5.464

4.  Ivacaftor Alters Macrophage and Lymphocyte Infiltration in the Lungs Following Lipopolysaccharide Exposure.

Authors:  Kiera H Harwood; Rachel M McQuade; Andrew Jarnicki; Elena K Schneider-Futschik
Journal:  ACS Pharmacol Transl Sci       Date:  2022-06-10

5.  Neutrophil Elastase Triggers the Release of Macrophage Extracellular Traps: Relevance to Cystic Fibrosis.

Authors:  Apparao B Kummarapurugu; Shuo Zheng; Jonathan Ma; Shobha Ghosh; Adam Hawkridge; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 7.748

6.  Alterations in innate immune responses of patients with chronic rhinosinusitis related to cystic fibrosis.

Authors:  Gustavo L Rezende; Marcio Nakanishi; Shirley C P Couto; Carmen L F S Martins; André L L Sampaio; Lucas F F Albuquerque; Selma A S Kückelhaus; Maria I Muniz-Junqueira
Journal:  PLoS One       Date:  2022-05-06       Impact factor: 3.240

Review 7.  Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation.

Authors:  Carla M P Ribeiro; Bob A Lubamba
Journal:  Int J Mol Sci       Date:  2017-01-09       Impact factor: 5.923

Review 8.  Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease.

Authors:  Michael C McKelvey; Ryan Brown; Sinéad Ryan; Marcus A Mall; Sinéad Weldon; Clifford C Taggart
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

9.  CF monocyte-derived macrophages have an attenuated response to extracellular vesicles secreted by airway epithelial cells.

Authors:  Katja Koeppen; Amanda Nymon; Roxanna Barnaby; Zhongyou Li; Thomas H Hampton; Alix Ashare; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-01-20       Impact factor: 6.011

Review 10.  Immunomodulation in Cystic Fibrosis: Why and How?

Authors:  Vincent D Giacalone; Brian S Dobosh; Amit Gaggar; Rabindra Tirouvanziam; Camilla Margaroli
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.